Evidence map›Paper›PMID 39856320›Full record

ArticleScientific reports2025

Decreased PD-L1 contributes to preeclampsia by suppressing GM-CSF via the JAK2/STAT5 signal pathway.

Yingying Tian, Xu Peng, Xiuhua Yang

Erratum issuedAbstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Systemic and Local Immunological Markers in Preeclampsia.Diagnostics (Basel, Switzerland) · 2025
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Yingying Tian *Department of Obstetrics, The First Hospital of China Medical University, Shenyang, 110000, Liaoning, China.
Xu Peng *Department of Obstetrics, The First Hospital of China Medical University, Shenyang, 110000, Liaoning, China.
Xiuhua YangDepartment of Obstetrics, The First Hospital of China Medical University, Shenyang, 110000, Liaoning, China. xhyang@cmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Programmed cell death protein 1 (PD-1) and its ligand PD-L1 have been detected at the materno-embryonic interface in both human and murine pregnancy models. However, research regarding the PD-1/PD-L1 signal in preeclampsia (PE) is limited. In the present investigation, 30 normal pregnant females and 30 PE patients were enrolled. Cellular functional experiments were performed in two trophoblast cell lines by transfection with lentiviral vectors for overexpression and down-regulation of PD-L1. The placental expressions of PD-1, PD-L1, and granulocyte macrophage colony-stimulating factor (GM-CSF) exhibited a notable reduction in PE cases compared with healthy pregnancies. Cellular functional experiments indicated that excessive PD-L1 expression significantly enhanced trophoblast migratory, invasive, and proliferative capabilities while inhibiting cell apoptosis. Additionally, the administration of lentivirus-mediated PD-L1 overexpression could alleviate clinical symptoms (hypertension, proteinuria) of PE-like rats. Therefore, decreased PD-L1 may contribute to PE by inhibiting GM-CSF via activating the JAK2/STAT5 pathway. Our study provides a novel pathway that can be targeted for the therapy of this disease.

Indexed as

B7-H1 AntigenGranulocyte-Macrophage Colony-Stimulating FactorJanus Kinase 2Pre-EclampsiaSignal TransductionSTAT5 Transcription FactorAdultAnimalsApoptosisCell LineCell MovementCell ProliferationFemaleHumansPlacentaPregnancyB7-H1 AntigenCD274 protein, humanGranulocyte-Macrophage Colony-Stimulating FactorJAK2 protein, humanJanus Kinase 2STAT5 Transcription FactorGM-CSFPD-L1PlacentaPreeclampsiaPregnancy

Identifiers

PMID39856320
PMCPMC11759946

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.